Live Breaking News & Updates on Receptor Antagonists

Stay updated with breaking news from Receptor antagonists. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pharvaris Announces Extraordinary Meeting of Shareholders

ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST (6:00 a.m. EST). All relevant documents and information relating to the extraordinary general meeting, including the notice and agenda for the extraordinary ....

Extraordinary General Meeting , Receptor Antagonists ,

Pharvaris To Present at the APAAACI 2023 International Conference

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of an abstract oral presentation at the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) and Allergy and Clinical Immunology Society of Singapore (ACIS) APAAACI 2023 International Conference, to be held from October 23-2 ....

Marcus Maurer , Exhibition Center , Asia Pacific Association Of Allergy , International Conference , Clinical Immunology Society Of Singapore , Suntec Singapore International Convention , Asia Pacific Association , Clinical Immunology , Clinical Immunology Society , Oral Presentation , Receptor Antagonists , Asia Pacific Association Of Allergy , International Conference , Untec Singapore International Convention And Exhibition Center ,